Tyra Biosciences Advances Bladder Cancer Drug to Pivotal Trial Despite Stock Drop
Accepting lower efficacy than rival pan-FGFR inhibitors allows Tyra to position dabogratinib on a superior safety profile, trading top-line response for zero treatment-related discontinuations.
Tyra Biosciences will advance its bladder cancer drug dabogratinib to a registrational study next year after reporting initial Phase 2 data that missed Wall Street targets. The trial tests the oral, FGFR3-selective inhibitor in low-grade intermediate-risk non-muscle-invasive bladder cancer across 50-mg and 60-mg arms. Investors sent Tyra stock down 38% to $19.30 at market open Wednesday from a Tuesday close of $26.73, after the pooled complete response rate fell short of the 70% set by analysts. H.C. Wainwright and Guggenheim analysts established that threshold using Johnson & Johnson's THOR-2 study of Balversa, a pan-FGFR inhibitor that achieved a 72% complete response rate but drew criticism for off-target toxicity. Tyra reported grade 3 or worse treatment-emergent adverse events of 9% in the 50-mg arm and 14% in the 60-mg cohort, with no dose reductions or treatment-related discontinuations in the 60-mg group. The company identified the 60-mg dose for its registrational adjuvant development strategy and plans to enroll a 70-mg cohort to assess the drug in an ablative setting.
Tyra Biosciences Share Price ($)
Tyra shares fell 38% following the Phase 2 data release.
Biocon Secures 10-Year Pertuzumab Supply Contract in Brazil
Structuring biosimilar entry around Brazil's public partnership model trades eventual technology transfer for immediate procurement exclusivity, replacing volatile drug tenders with long-term sovereign cash flows.
Biocon has secured a 10-year supply contract for the breast cancer drug Pertuzumab in Brazil through a consortium with Bahiafarma and Bionovis. The consortium secured 100 percent allocation under Brazil's Productive Development Partnership programme, granting the group exclusive access to the public healthcare market that accounts for roughly 70 percent of national demand for the therapy. Biocon will receive milestone payments and a share of revenues generated over the duration of the agreement. Pertuzumab is currently not manufactured locally, creating a significant expenditure for Brazil's Unified Health System known as SUS. The framework requires phased localisation of production over the medium to long term to build domestic biopharmaceutical manufacturing capabilities.
Encoded Closes $275 Million Series F to Advance Dravet Syndrome Drug
Demonstrating clinical efficacy before raising mega-rounds allows monogenic gene therapy developers to command late-stage capital even after severe early-stage cost restructuring.
Encoded Therapeutics closed a $275 million Series F financing round to fund a pivotal study of its Dravet syndrome drug and expand internal manufacturing capabilities. GV and an undisclosed healthcare fund co-led the round, with participation from ARCH Venture Partners, Janus Henderson Investors, RTW Investments, and SoftBank Vision Fund. The will advance ETX101, an AAV9-based gene therapy for SCN1A-positive Dravet syndrome, alongside an investigational new drug application submission for ETX301 planned for 2027. The financing follows a workforce reduction of 29% in February 2025 that preserved capital for earlier clinical development. That trial subsequently produced a 78% reduction in seizures.
Kura Oncology Launches $50 Million Lilly-Backed Diabetes Spinout
Splitting metabolic assets into a Lilly-backed vehicle protects oncology margins while keeping exposure to a menin inhibitor's potential transition into chronic disease treatment.
Kura is spinning out its diabetes pipeline into a new biotech called Caspian Therapeutics with $50 million in initial financing. The funding round was led by BVF Partners and included Eli Lilly, the T1D Fund, Invus, Montanova, and members of Kura's leadership team. Caspian will use the to advance its lead menin inhibitor, KO-7246, through early-phase in diabetes and cardiometabolic diseases. Kura originally observed that targeting menin, a protein involved in cell division, controlled blood sugar levels in animal studies alongside its known effects against leukemia. Kura will retain about 50 percent ownership of the new spinout. Kura CEO Troy Wilson will serve as executive chair of Caspian's board, while Robert Spencer will lead the company as head. The spinout allows Kura to focus on rolling out its leukemia drug Komzifti while external capital funds the diabetes research.
FDA Permanently Appoints Acting Heads for Drug and Vaccine Centers
Permanent leadership at the drug and biologics oversight divisions provides regulatory predictability for biotech pipelines while establishing a dedicated office to accelerate tech-driven trial reviews.
The Trump administration named Michael Davis and Karim Mikhail as permanent directors of the Center for Drug Evaluation and Research and the Center for Evaluation and Research on September 8, 2026. Both officials had been running the divisions on an interim basis since May following a period of turnover that included the resignation of former commissioner Marty Makary. The Health and Human Services Department also appointed Jared Seehafer as the agency's first deputy commissioner for technology and , alongside Bret Koplow as director of the Center for Tobacco Products. Analysts noted the appointments should bring stability and a return to more flexible regulatory decision-making while the industry awaits the Senate confirmation of Heidi Overton as permanent commissioner.
Boston Scientific Unlikely to Meet 2026 Targets Following Cyberattack
When physical sterilization and distribution backlogs force analysts to write off a medical device maker's entire fiscal year, operational downtime becomes a multi-quarter valuation reset.
Boston Scientific will miss its full-year 2026 sales and targets following a cyberattack that paralyzed its global manufacturing and shipping operations. An unauthorized intrusion on August 25 knocked out key business applications and forced the medical device maker to halt customer order processing. While major distribution centers and sterilization facilities have resumed normal operations, the resulting has clouded the company's financial visibility. Stifel analyst Rick Wise told clients that investors now view 2026 as a lost year and are shifting their focus to 2027 prospects. Boston Scientific plans to issue revised when it reports third-quarter earnings on October 28.
Beeline Medicines Advances Lupus Drug to Phase 3 Following Promising Data
Advancing an acquired TLR inhibitor into final-stage clinical trials validates spin-out development models that rely on venture funding to scale big-pharma assets without early licensing partners.
Beeline Medicines is advancing its oral lupus drug afimetoran into development after the candidate hit its primary endpoint in a phase 2 trial. The trial tested the small-molecule inhibitor of Toll-like receptors 7 and 8 against a placebo across 48 weeks of daily treatment in patients with systemic lupus erythematosus. All three doses of afimetoran produced significantly higher SRI-4 response rates than the placebo cohort, with a p-value of less than 0.001. Beeline acquired afimetoran alongside four other from Bristol Myers Squibb as part of a that was backed by a $300 million launch in April and a $126 million series A extension in June. While competitors including Germany's Merck KGaA have advanced rival treatments into phase 3, Beeline executives intend to retain solo control over the asset's path to regulatory approval.
SuMarket writes Healthcare and Pharmaceutical Sector every morning, along with every other section of the market and the companies and topics you follow. Free to read.